Your browser doesn't support javascript.
loading
Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study.
Fu, Rui; Huang, Jun; Tian, Xiaoru; Liang, Chaoyang; Xiong, Yuanyuan; Zhang, Jia-Tao; Jiang, Benyuan; Dong, Song; Gong, Yuhua; Gao, Wei; Li, Fang; Shi, Yonglei; Liu, Zhentian; Gao, Xuan; Chen, Rongrong; Zhong, Wenzhao; Zhang, Yi.
Afiliación
  • Fu R; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • Huang J; School of Medicine, South China University of Technology, Guangzhou, China.
  • Tian X; Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, China.
  • Liang C; Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Xiong Y; Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China.
  • Zhang JT; Geneplus-Beijing, China.
  • Jiang B; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • Dong S; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • Gong Y; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • Gao W; Geneplus-Beijing, China.
  • Li F; Geneplus-Beijing, China.
  • Shi Y; Geneplus-Beijing, China.
  • Liu Z; Geneplus-Beijing, China.
  • Gao X; Geneplus-Beijing, China.
  • Chen R; Geneplus-Beijing, China.
  • Zhong W; Geneplus-Beijing, China.
  • Zhang Y; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Mol Oncol ; 17(5): 825-838, 2023 05.
Article en En | MEDLINE | ID: mdl-36732646
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: ADN Tumoral Circulante / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Mol Oncol Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: ADN Tumoral Circulante / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Mol Oncol Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: China